|(Z)-5-(5-((3-(4-溴苯基)-2-亚氨基-4-氧代噻唑烷-5-亚基)甲基)呋喃-2-基)异吲哚啉-1,3-二酮|CsnPharm

CAS No.: 1420071-30-2

Synonyms: DR5 Activator

Bioymifi is an activatior of the TRAIL receptor DR5 in cancer cells.

规格	价格	促销价格	库存	数量

400-920-2911

加入购物车大规格询价

产品咨询

400-920-2911

纯度 & 质量文件批次:

生物活性

描述TNF-related apoptosis-inducing ligand (TRAIL, APO2L) is a member of the TNF cytokine superfamily，and is involved in pathogenesis of and/or possible treatment approaches for a variety of diseases including but not limited to cancer, obesity, diabetes, rheumatoid arthritis, and neurodegenerative diseases^[2]. TRAIL secreted from natural killer (NK) cells binds to death receptors (DR4 or DR5). Bioymifi is an activator of the TRAIL receptor DR5 for cancer therapy. Bioymifi bound the extracellular domain (ECD) of DR5 with a K_d of 1.2 μM^[3]. Human glioblastoma cells T98G cells, lung cancer cell lines H460 and H1155, the cervical cancer cell line HeLa, the osteosarcoma cell line U2OS, the pancreatic carcinoma cell line Miapaca and the colon cancer cell line HT29 showed single-agent sensitivity to bioymifi which is dependent on caspase-8^[3]. Caspase-3 was rapidly activated as early as 2 h after bioymifi treatment (5 μM) of T98G cells and its activity was markedly increased after 8 h of treatment^[3].
作用机制Bioymifi bound the extracellular domain (ECD) of DR5.
参考文献

实验方案

技术信息

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

请登录您的专属账户